Targeted drug combo for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs: an antibody-drug conjugate (RC48-ADC) that targets HER2 on cancer cells, plus an immunotherapy (Zimberelimab) that helps your immune system attack the cancer. It is for people with advanced cervical cancer whose prior platinum-based chemotherapy has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have cervical cancer that has come back or spread to other parts of the body.
- You have already had at least one type of chemotherapy with platinum, which no longer works or you can't take it.
- Your tumor must have a specific protein called HER2 on its surface (tested in a central lab).
- You are at least 18 years old, able to do daily activities with little to no help (ECOG 0 or 1), and expected to live at least 12 weeks.
- Your main organs (like blood cells, kidneys, liver, and heart) must be working well enough to handle the treatment.
- You cannot have cancer that has spread to your brain, active infections, or other serious health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding the immunotherapy drug Zimberelimab to standard chemoradiation after surgery for locally advanced cervical cancer. It aims to see if this combination helps prevent the cancer from coming back.
This trial tests a combination of three types of cancer-fighting drugs—an immunotherapy (camrelizumab), a targeted therapy (famitinib), and chemotherapy—to treat cervical cancer that has returned or spread. The goal is to see if this combination works better than standard treatment.
This Phase 2 trial tests cadonilimab (an immunotherapy medicine) combined with anlotinib (a targeted drug) for advanced or recurrent cervical cancer that has already been treated. It may help shrink tumors or slow cancer growth, especially if the cancer has a measurable area doctors can track.
This trial tests a combination of cadonilimab (an immune-boosting drug) plus chemotherapy for locally advanced cervical cancer that hasn't been treated before. The goal is to see if this combination helps shrink tumors and improve outcomes before surgery.
This trial tests combining two drugs (nituzumab and serplulimab) with focused radiation to treat cervical cancer that has not responded to other therapies. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests a combination of two drugs, disitamab vedotin and bevacizumab, for people with a specific type of advanced breast cancer called HER2-low. It is designed for those who have already been treated with a drug called T-DXd and need further options.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.